AU2003224761A1 - Mcp-1 mutant proteins, antibodies, compositions, methods and uses - Google Patents

Mcp-1 mutant proteins, antibodies, compositions, methods and uses

Info

Publication number
AU2003224761A1
AU2003224761A1 AU2003224761A AU2003224761A AU2003224761A1 AU 2003224761 A1 AU2003224761 A1 AU 2003224761A1 AU 2003224761 A AU2003224761 A AU 2003224761A AU 2003224761 A AU2003224761 A AU 2003224761A AU 2003224761 A1 AU2003224761 A1 AU 2003224761A1
Authority
AU
Australia
Prior art keywords
mcp
antibodies
compositions
methods
mutant proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003224761A
Other languages
English (en)
Other versions
AU2003224761A8 (en
Inventor
Anuk Das
George A. Heavner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of AU2003224761A8 publication Critical patent/AU2003224761A8/xx
Publication of AU2003224761A1 publication Critical patent/AU2003224761A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003224761A 2002-03-26 2003-03-24 Mcp-1 mutant proteins, antibodies, compositions, methods and uses Abandoned AU2003224761A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36793202P 2002-03-26 2002-03-26
US60/367,932 2002-03-26
PCT/US2003/009056 WO2003083059A2 (fr) 2002-03-26 2003-03-24 Proteines de mutants de mcp-1, anticorps, compositions, procedes et utilisations

Publications (2)

Publication Number Publication Date
AU2003224761A8 AU2003224761A8 (en) 2003-10-13
AU2003224761A1 true AU2003224761A1 (en) 2003-10-13

Family

ID=28675424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003224761A Abandoned AU2003224761A1 (en) 2002-03-26 2003-03-24 Mcp-1 mutant proteins, antibodies, compositions, methods and uses

Country Status (3)

Country Link
EP (1) EP1497423A4 (fr)
AU (1) AU2003224761A1 (fr)
WO (1) WO2003083059A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
EP1926747A1 (fr) 2005-08-12 2008-06-04 Schering Corporation Fusions de mcp1
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413778A (en) * 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
US6174995B1 (en) * 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US5688927A (en) * 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
WO1999005279A1 (fr) * 1997-07-25 1999-02-04 Zeneca Limited Analogues de mcp-1

Also Published As

Publication number Publication date
AU2003224761A8 (en) 2003-10-13
WO2003083059A2 (fr) 2003-10-09
EP1497423A2 (fr) 2005-01-19
WO2003083059A3 (fr) 2004-10-07
EP1497423A4 (fr) 2006-05-24

Similar Documents

Publication Publication Date Title
WO2004040000A9 (fr) Recepteurs couples a la proteine g et leurs utilisations
EP1578930A4 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
AU2002354929A1 (en) Antibodies specific for nanotubes and related methods and compositions
HK1079213A1 (en) Anti-il-6 antibodies, compositions, methods and uses
EP1623011A4 (fr) Proteines derivees de l'immunoglobine specifiques de il-23p40, compositions, procedes et utilisations
AU2003220205A1 (en) Ethanol-diesel fuel composition and methods thereof
AU2002314825A1 (en) Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
WO2005081873A9 (fr) Proteines et anticorps de la muteine il-13, compositions, methodes et applications
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2003253621A1 (en) Modified "s" antibodies
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002336658A1 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
AU2003224313A1 (en) Mycobacterial antigens and uses thereof
WO2004003149A8 (fr) Polypeptides cngh0005, anticorps, compositions, methodes et utilisations
AU2003297079A1 (en) Anti-filming materials, compositions and methods
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002345878A1 (en) Ilt3 and ilt4-related compositions and methods
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2003224761A1 (en) Mcp-1 mutant proteins, antibodies, compositions, methods and uses
AU2003220557A8 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
AU2002365925A1 (en) Rsv proteins, antibodies, compositions, methods and uses
EP1694845B8 (fr) Anticorps anticarcinomes et leurs utilisations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase